Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,204,527 papers from all fields of science
Search
Sign In
Create Free Account
ECOG performance status
Known as:
ECOG Score
, ECOG1-Performance Status
, ECOG101
Expand
A performance status scale designed to assess disease progression and its affect on the daily living abilities of the patient.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
CDISC Questionnaire ECOG Test Code Terminology
Clinical Data Interchange Standards Consortium Terminology
Zubrod Performance Status
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412)
C. Diefenbach
,
Fangxin Hong
,
+12 authors
S. Ansell
Hematological Oncology
2019
Corpus ID: 196558631
phoma (Frank, Cancer Discov, 2018). Ibrutinib compromises B-cell survival by inhibiting Bruton’s tyrosine kinase, but also…
Expand
Review
2019
Review
2019
Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy.
S. Moore
,
B. Leung
,
Jonn Wu
,
C. Ho
Journal of Thoracic Oncology
2019
Corpus ID: 124128363
2019
2019
Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin‐2 use in solid tumors: A feasibility off‐label experience
G. Re
,
Francesco Lo Re
,
+8 authors
P. Sandri
Cytokine
2019
Corpus ID: 49617729
2015
2015
Risk of acute myocardial infarction after androgen‐deprivation therapy for prostate cancer in a Chinese population
J. Teoh
,
S. Y. Chan
,
+4 authors
C. Ng
BJU International
2015
Corpus ID: 8079039
To investigate the risk of acute myocardial infarction (AMI) after androgen‐deprivation therapy (ADT) for prostate cancer in a…
Expand
2015
2015
Tolerability and outcomes of curative radiotherapy in patients aged 85 or more years
R. Khor
,
M. Bressel
,
+6 authors
F. Foroudi
Medical Journal of Australia
2015
Corpus ID: 23049512
Objectives: To assess the tolerability and survival outcome of curative radiotherapy in patients over the age of 85 years.
2013
2013
Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
D. Chen
,
P. Zhao
,
+4 authors
L. Liang
European Journal of Surgical Oncology
2013
Corpus ID: 25654638
Review
2013
Review
2013
Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years).
P. Aridgides
,
A. Janik
,
J. Bogart
,
Steven M. Duffy
,
P. Rosenbaum
,
A. Gajra
Clinical Lung Cancer
2013
Corpus ID: 5386189
2011
2011
A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC.
J. von Pawel
,
Z. Pápai-Székely
,
+5 authors
C. Dittrich
Journal of Clinical Oncology
2011
Corpus ID: 36435360
7526 Background: PEM and ERL have been approved as second-line monotherapy for locally advanced or metastatic NSCLC. The…
Expand
2008
2008
Phase 2 trial of docetaxel and gefitinib in the first‐line treatment of patients with advanced nonsmall‐cell lung cancer (NSCLC) who are 70 years of age or older
G. Simon
,
M. Extermann
,
+8 authors
G. Bepler
Cancer
2008
Corpus ID: 12270895
This is a phase 2 study of chemotherapy‐naive patients, 70 years of age or older, with nonsmall‐cell lung cancer (NSCLC) who were…
Expand
2004
2004
Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil
A. Mori
,
S. Bertoglio
,
+5 authors
A. Sobrero
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 19112592
We have recently demonstrated that continuous-infusion (CI) 5-fluororacil (FU) eradicates human colon carcinoma cells made…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE